FDA Wants More "Predictable" Revenue Stream Under PDUFA III
This article was originally published in The Tan Sheet
Executive Summary
FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.
You may also be interested in...
User Fees Should Recognize Complete Product Life Cycle - FDA's Feigal
The design of FDA's user fee system should encourage attention to the entire life cycle of a product, Center for Devices & Radiologic Health Director David Feigal, MD, said at the Food & Drug Law Institute meeting in Washington, D.C. June 5.
User Fee Revision Reduces Expected CDER Staffing Increases By 60%
A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC